Oncology CME

  • FEATURED

    BoardVitals Hematology and Oncology CME Board Review

    The BoardVitals Hematology and Oncology CME Review offers clinicians 27 AMA PRA Category 1 CreditsTM, 27 ABIM MOC points, and over 500 Hematology and Oncology board review questions. The questions cover key topics including Breast Cancer, Gynecologic Cancer, and Transfusion Medicine. This question bank will assist clinicians with Hematology and Oncology certification and recertification.

    The BoardVitals Hematology and Oncology CME Review also features:

    • Quick and Convenient CME
    • Computer, phone, and tablet access
    • Constantly updated up-to-date questions
    • Questions that are targeted specifically to the exam
    • Online CME tracker
    • 100% Pass Guarantee
    • Statistical comparison to other Hematology and Oncology test-takers (Nationally)

     

    After completing this activity, you should be able to:

    • Make a diagnosis
    • Order and interpret results
    • Assess risk, determine prognosis, and apply principles from epidemiologic studies
    • Describe the underlying pathophysiology of disease and basic science knowledge

     

    Target Audience: Hematologists and Oncologists

    See full details chevron_right
    • Cost: $599
    • Credit hours: 27
    • CME credits awarded by: BoardVitals
    • Format: On-Demand Online
    • Material last updated: Continuously Updated
  • Oakstone MKSAP® 19 Audio Companion

    Expert Advice and Insightful Commentary

    The MKSAP® 19 Audio Companion sheds light on the latest diagnostic approaches, management strategies, and treatment guidelines. In this comprehensive audio CME program, you’ll join host Donald L. Deye, MD, FACP, as he leads lively discussions with esteemed colleagues in 11 internal medicine subspecialties. Listen as experienced clinicians from some of the world’s finest medical institutions share patient stories, insightful views of recent clinical advances, and more.

    Anytime, Anywhere Audio CME

    With the MKSAP 19 Audio Companion, you get:

    • All-new advice and commentary — a reliable, and entertaining way to learn current oncology trends, the latest approaches to diabetes treatment, COVID updates, new tactics for managing patients with COPD, and so much more
    • An easy way to prep for your ABIM certification or MOC exam
    • Flexible learning to fit your schedule — in your car, between appointments, while you work out
    • Companion booklets — high-impact PDF learning aids to quickly review and retain key points (print booklets available for an additional charge)
    • The opportunity to earn AMA PRA Category 1 Credits and ABIM MOC points
    • Four FREE sets of extension questions — a $350 value that brings you incremental AMA PRA Category 1 Credits™ and MOC points

    Audience

    General internists and primary care physicians; subspecialists who need to remain up to date in internal medicine; residents preparing for the certifying examination in internal medicine; physicians preparing for the recertification examination. 

    Learning Objectives

    • Discuss the most clinically relevant patient care information in all subspecialties of Internal Medicine based on the medical literature of the last 3 to 5 years
    • Describe clinical situations in which this new knowledge will improve quality of care
    • Diagnose disease states that are less common and sometimes overlooked and confusing
    • Determine when to refer patients for surgery or care by subspecialists
    See full details chevron_right
    • Cost: $1297
    • CME credits awarded by: Oakstone Publishing, LLC
    • Format: On-Demand Online, Online Audio, Audio CD
    • Material last updated: Part A Release: August 31, 2021 Part B Release: January 31, 2022
    • Expiration of CME credit: Expiration Date: August 31, 2024 Expiration Date: December 31, 2024
  • StatPearls Unlimited Physician MD/DO/PA CME

    Stay on top of your game with the StatPearls Physician Unlimited CME programs. With 6,046 activities, StatPearls is the largest CME provider in the world. These Pub-Med Indexed articles are categorized into 162 specialty areas which lets you better access activities that will make the biggest impact on your practice. One subscription allows access to all the activities, including all state-requirements.

    Pricing Options

    • 6 Month subscription: All 6,339 CME Activities $249 per 6 months
    • Annual subscription: All 6,339 CME Activities $349 per 1 year
    • Lifetime: All 6,339 CME Activities + Access to Board Reviews Forever $1999
    See full details chevron_right
    • Cost: Varies
    • CME credits awarded by: ETSU
    • Format: On Demand Online & Board Reviews
  • Oakstone CME Molecular Diagnostics: Cancer Diagnosis and Patient Management

    Learn Now: Advances in Molecular Diagnostics

    In Molecular Diagnostics: Cancer Diagnosis and Patient Management, experts in the field review current concepts and up-to-date techniques, delving into the appropriate use of molecular assays for different tumor types to inform diagnosis, prognosis, or treatment using evidence-based guidelines.

    Lectures in this online CME course illustrate common diagnostic pitfalls, with additional focus on variant interpretation and the complexity of billing for molecular tests. It’s continuing medical education that will help you to:

    • Develop appropriate tissue-handling protocols
    • Evaluate cytogenetic and molecular techniques, including next generation sequencing assays
    • Recognize cost-effective, time-sensitive approaches to molecular studies, including cell free DNA testing
    • Determine the process of clinical interpretation of genetic variation
    • Analyze costs and potential sources of revenue for molecular diagnostics programs
    • Consider essential and emerging biomarkers in common adult and pediatric solid and liquid tumors
    See full details chevron_right
    • Cost: $895
    • Credit hours: 18
    • CME credits awarded by: Oakstone Publishing, LLC.
    • Material last updated: October 30, 2021
    • Expiration of CME credit: January 31, 2024
  • SAVE 15% W/ CODE: CME15

    Oakstone CME The Brigham and Dana-Farber Board Review and Comprehensive Update in Oncology

    Key Topics in Oncology CME

    The Brigham and Dana-Farber Board Review and Comprehensive Update in Oncology is an online CME course designed to update knowledge and improve management strategies. This collection of case-based presentations — presented by a distinguished faculty of experts — will help enhance patient care while you prep for your board exam. It’s continuing medical education that helps you to:

    • Apply recommended oncology guidelines in clinical practice
    • Perform differential diagnosis of complex oncologic disorders
    • Identify and apply current therapeutic options for oncologic disorders
    • Evaluate and interpret up-to-date literature relevant to oncology
    • Illustrate knowledge of pathophysiology as it applies to management of oncology disorders
    • Apply knowledge gained to the ABIM certification/recertification oncology examinations

    This program is also available as part of the combined Brigham and Dana-Farber Board Review and Comprehensive Update in Hematology and Oncology CME course found here.

    See full details chevron_right
    • Cost: $1295
    • Credit hours: 29
    • CME credits awarded by: Oakstone Publishing
    • Format: On-Demand Online, Online Video, Online Audio, Audio CD
    • Material last updated: July 15, 2022
    • Expiration of CME credit: July 15, 2025
  • New Vistas in Prostate Cancer Imaging

    Penn Radiology Emergency Imaging After Hours provides insight for imaging conditions where rapid response is required. An elite faculty guides learners with practical lessons in modality choice, image acquisition and interpretation skills for a wide range of clinical presentations. Selected topics in chest, neuroradiology, abdominal, pelvic, pediatric and musculoskeletal imaging are presented to ensure confident analysis, so the practitioner is never outside of their comfort zone. Worth up to 15.75 AMA PRA Category I Credits™, all applicable as SA-CME for Maintenance of Certification requirements.

    See full details chevron_right
    • Cost: $595
    • Credit hours: 15
    • CME credits awarded by: Global Education Group
    • Format: On-Demand Online
    • Material last updated: 5/1/2022
    • Expiration of CME credit: 4/30/2025
  • Penn Radiology Oncologic Imaging Essentials

    Penn Radiology responds to the constant challenge of Cancer imaging with Oncologic Imaging Essentials.  This activity includes a review of the diagnostic imaging evaluation of common tumors, including breast, head and neck, thoracic and abdominal malignancies.  Current state of the art modalities used for oncologic imaging, including CT, MRI, ultrasound, PET-CT and digital mammography will be discussed.  Emphasis is placed on the role of imaging in staging, treatment and follow up in order to optimize care of oncologic patients.

     

    See full details chevron_right
    • Cost: $595
    • Credit hours: 18
    • CME credits awarded by: Global Education Group
    • Format: On-Demand Online
    • Material last updated: 4/15/20
    • Expiration of CME credit: 4/14/23
  • FREE

    Treating Oncology Patients During COVID-19

    Activity Description / Statement of Need: The COVID-19 pandemic has led to unprecedented changes in health care delivery worldwide, affecting the way that nearly every medical specialty can safely practice. As with other fields of medicine, oncology has its own challenges in navigating the pandemic. Based on pre-pandemic estimates, 1.8 million new cancer diagnoses would be expected in 2020, equating to approximately 5,000 new cancer diagnoses per day. Evidence thus far suggests that COVID-19 is associated with significantly more complications and a higher risk of death in patients with cancer or with a history of cancer. Furthermore, patients with cancer have also been shown to have a higher COVID-19 infection rate than the general population, suggesting increased susceptibility, potentially due to immunosuppression, comorbidities, or poor health status related to cancer or its treatment. Based on these data, oncology specialists are said to be fighting “a war on two fronts” by balancing the risks of COVID-19 transmission and acquisition with the risks of delayed cancer diagnosis and treatment. This represents an unmet need among oncology practitioners as they navigate this new health care landscape.

    Target Audience:

    Healthcare professionals, including medical oncologists; radiation oncologists; surgical oncologists; surgeons; radiologists; nuclear medicine specialists; nurse practitioners and physician assistants who practice in oncology; and other healthcare providers who manage cancer.

    By the end of the session the participant will be able to:

    • Recall the symptoms of COVID-19 infection and best practices for screening patients, health care providers, and staff in the oncology setting.
    • Develop a plan to provide oncology care in the setting of the COVID-19 pandemic.
    • Describe the risks of delaying cancer diagnosis and treatment against the risk of COVID-19 exposure and infection.
    • See full details chevron_right
    • Cost: Free
    • Credit hours: .75
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: 09/22/2020
    • Expiration of CME credit: 09/22/2022
  • FREE

    Addressing skeletal-related events in prostate cancer

    Each year, an estimated 170,000 cases of prostate cancer are diagnosed. Although early prostate cancer may be cured with surgery or radiation therapy, more than 50% of men will experience recurrence after definitive treatment. The use of androgen deprivation therapy (ADT) for intermediate-risk, high-risk, and recurrent prostate cancer has greatly increased in the last 15 years, extending 10-year survival by nearly 25% compared with observation alone. New treatment options for advanced prostate cancer have further improved survival and increased the number of patients living with non-metastatic and metastatic castration-resistant prostate cancer (nmCRPC and mCRPC). Despite the established improvements in survival associated with hormonal treatments, ADT has been associated with well-characterized negative effects on bone health. Indeed, bone metastases and subsequent skeletal-related events (SREs) are the primary driver of both morbidity and mortality among people with CRPC. In a study of 2234 men aged 65 years or older with a diagnosis of CRPC, 40% experienced SREs over a median follow-up of 10.6 months. Maintaining bone health in patients with CRPC requires routine monitoring and proactive management.

    Target Audience:

    The following healthcare professionals: urologists, medical and radiation oncologists, primary care physicians, nuclear medicine specialists and radiologists, and endocrinologists; physician assistants, nurse practitioners, and pharmacists who treat prostate cancer; and any other healthcare professionals who commonly care for patients with prostate cancer.

    By the end of the session the participant will be able to:

    • Recall the relative efficacy and safety of presently available agents used to for bone health and fracture prevention in patients with prostate cancer
    • Describe the identification and management of disease and intervention adverse effects on patients
    • Using details in a patient case, recommend an appropriate pharmacotherapeutic treatment plan for the purpose of preventing SREs in patients with prostate cancer
    See full details chevron_right
    • Cost: Free
    • Credit hours: .75
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: 07/31/2020
    • Expiration of CME credit: 07/31/2022
  • FREE

    Practice updates in treating advanced-stage gastric and gastroesophageal junction cancers

    Activity Description / Statement of Need:
    In this online, self-learning activity:

    Gastric cancer (GC) accounts for over 26,000 new cases and 11,000 related deaths in the U.S. annually, and while malignancies of the esophagus and gastroesophageal junction (GEJC) are associated with 19,000 and 15,000, respectively. GEJ tumors clinically more often resemble gastric than esophageal cancers, and GEJ cancers are often included in studies of GC. Adenocarcinomas represent more than 95% of gastric cancers and around 75% of esophageal cancers in the US. Systemic therapy is the mainstay of treatment for advanced and metastatic disease. There is a widening number of treatment options for GC and GEJC with approved and investigational agents. This learning activity has therefore been designed to bring HCPs’ knowledge of the rationale behind treatment of GC and GEJC up to date and to enhance their competence and performance in the management of it.

    Target Audience:
    HCPs including: Medical oncologists, pathologists, physician assistants, nurse practitioners, and pharmacists specializing in oncology; and any other clinicians involved or interested in the treatment of GC & GEJC.

    See full details chevron_right
    • Cost: Free
    • Credit hours: 1.25
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: 10/31/2021
    • Expiration of CME credit: 10/31/2022